Tinjauan Ke Hospital Sungai Buloh

https://www.najibrazak.com/bm/blog/tinjauan-ke-hospital-sungai-buloh/

Petang tadi, saya sempat meluangkan masa membuat tinjauan ke Unit Hemodialisis Hospital Sungai Buloh bagi melihat sendiri keadaan di sana.

Saya difahamkan bahawa ramai pesakit buah pinggang yang perlu menunggu lama sebelum giliran mereka untuk mendapatkan rawatan hemodialisis di hospital-hospital Kerajaan.

Isu ini timbul disebabkan terdapat lebih 2.5 juta pesakit buah pinggang di Malaysia dan ini membawa kepada permintaan tinggi di hospital-hospital Kerajaan yang memberikan rawatan dan perkhidmatan berkualiti pada kadar yang amat rendah, kira-kira 22 kali lebih rendah berbanding hospital-hospital swasta.

Kerajaan sedar bahawa bilangan mesin hemodialisis yang sedia ada di Hospital Sungai Buloh adalah tidak mencukupi untuk menampung keperluan pesakit-pesakit buah pinggang. Oleh itu, saya telah mengarahkan penambahan beberapa unit mesin hemodialisis yang baru untuk dihantar ke Hospital Sungai Buloh dalam masa terdekat.

Insya-Allah, saya yakin langkah ini akan membawa manfaat kepada pesakit-pesakit yang memerlukannya.

SivaSanta Dialysis and Medical Clinic project gets nod

BY RAVIN PALANISAMY

The Malaysian Insider

Published: 24 November 2015 7:01 AM

.Artist impression of the SivaSanta Dialysis and Medical Clinic, which will cost an estimated RM15 million to build and equip, on Jalan Berhala in Brickfields, Kuala Lumpur. – The Malaysian Insider pic by Ravin Palanisamy, November 24, 2015.After three years, Temple of Fine Arts Malaysia has finally received the nod from City Hall to proceed with its plan to redevelop Klinik Derma SivaSanta on Jalan Berhala in Brickfields, Kuala Lumpur.

The proposed three-storey facility will be known as SivaSanta Dialysis and Medical Clinic. It will offer general and specialist medical services, dialysis, diagnostic services, rehabilitation care and traditional and complementary medicine.

- See more at: http://www.themalaysianinsider.com/citynews/greater-kl/article/sivasanta-dialysis-and-medical-clinic-project-gets-nod#sthash.w68tvuB4.dpuf

read full text here

Diversifying the Global Heparin Supply Chain: Reintroduction of Bovine Heparin in the United States?

The global supply chain for bovine and porcine heparin and regulatory considerations are examined.

Nov 02, 2015

By David Keire, Barbara Mulloy, Christina Chase, Ali Al-Hakim, Damian Cairatti,Elaine Gray, John Hogwood, Tina Morris, Paulo Mourão, Monica Da Luz Carvalho Soares, Anita Szajek

Pharmaceutical Technology

Volume 39, Issue 11

Courtesy of the US Pharmacopeial Convention.Heparin regulates hemostasis at various points of the coagulation cascade mainly through its interaction with antithrombin and heparin cofactor II. Because of these properties, heparin is a life-saving anticoagulant drug used in renal dialysis, cardiac surgery, and treatment for deep vein thrombosis. The drug also binds to platelets, inhibiting platelet function and contributing to the hemorrhagic effects of heparin. Bovine heparin, first approved in 1939, was widely used in the United States for more than 50 years (see Figure 1). Like all drugs, heparin can cause adverse effects, but overall, bovine heparin products were found to be safe and effective during that period.

Figure 1: Historical development timeline of therapeutic heparin in United States.[Courtesy of Authors]Read the full text here

Aseptic Processing: Keeping it Safe

Humans represent the greatest risk for microbial contamination in an aseptic process.

By Randi Hernandez

BioPharm International 1/7/2015

submitted by Dr Syed Ibrahim Ismail

Aseptic processing has garnered some increased scrutiny from FDA in recent years, primarily because it is considered a high-risk activity by the agency, says Rainer Newman, consultant at Aseptic Process Technology, LLC. In addition, says Satish Singh, research fellow and group leader at Pfizer, “Microbiologically-related recalls have always been a significant portion of the enforcement actions by FDA.” In fact, more than 75% of FDA recalls during 2004–2011 involved sterile products, and approximately 80% of these recalls were linked to “lack of sterility assurance.” Many of the remaining 20% of recalls were attributed to microbial contamination or a failed fill/finish product test (1). Although packaging failures factored into a majority of the “lack of sterility assurance” cases, many of the remaining contamination cases were associated with GMP issues or manufacturing errors such as incomplete sterilization or nonsterile components being added to sterile products (1).

Read full article here

Baxter’s Phoxillum Renal Replacement Solutions obtains FDA approval

Pharmaceutical Technology

http://www.pharmaceutical-technology.com/news/newsbaxter-phoxillum-renal-replacement-4493678?WT.mc_id=DN_News

Baxter International has received approval from US Food and Drug Administration (FDA) for its Phoxillum Renal Replacement Solutions (BK4/2.5 and B22K4/0) to use as replacement solutions in continuous renal replacement therapy (CRRT).

The therapy aims to correct electrolyte and acid-base imbalances.

In addition, Phoxillum can be used in case of drug poisoning when CRRT is used to remove dialysable substances.

Baxter vice-president and renal therapeutic area lead Bruce Culleto said: "The approval of Phoxillum allows us to offer healthcare providers additional options in managing critically ill acute kidney injury patients treated with CRRT.

read full text here

Transplant recipient takes the lead in patient safety and best-care advocacy 

BY ELIZABETH ZACHARIAH 

When former club deejay J. Manvir underwent a kidney transplant at the Kuala Lumpur Hospital (KLH) two years ago, he was so surprised by the excellent treatment he received that he decided he wanted to do something to give back to the healthcare system. 

Read more here

Kidney transplant vs dialysis

September 21, 2014

http://www.freemalaysiatoday.com/category/leisure/2014/09/21/kidney-transplant-vs-dialysis/

Nobody is doing fine on dialysis to the point where a transplant wouldn’t be better for them.

In a new study, the vast majority of kidney failure patients told researchers they saw no need for a kidney transplant because they were doing fine on dialysis – but the researchers say these patients might not realize how much a transplant could help them.

“Nobody is doing fine on dialysis to the point where a transplant wouldn’t be better for them,” senior author Dr. Dorry Segev told Reuters Health. “Transplantation is the better form of renal replacement.”

A kidney transplant doubles a recipient’s life expectancy, said Segev, a transplant surgeon at the Johns Hopkins Hospital in Baltimore, Maryland.

His group’s study, published in the Clinical Journal of the American Society of Nephrology, showed a gap in dialysis patients’ knowledge about the benefits of transplants over dialysis, Segev said.

Researchers surveyed 348 patients being treated at 26 Baltimore-area freestanding dialysis centers, asking whether a dozen potential concerns constituted reasons they would not pursue a transplant. The average age was 56 and half the patients had been on dialysis for at least two months.

Overall, more than 68 percent of the patients told researchers “I’m doing fine on dialysis.”

The older the patient, the more likely they were to report feeling fine on dialysis, the study found.

Less educated patients were more likely to report being content with dialysis than those with higher degrees, the study found.

Almost a quarter of patients had not seen a nephrologist (a doctor who specializes in kidney disease) before starting dialysis – and these people were almost twice as likely to report that no one had discussed a possible transplant with them.

Nearly 30 percent of participants reported feeling uncomfortable asking a friend or relative to donate a kidney, the study found. The authors say such reluctance to ask friends and relatives to donate kidneys is consistent with prior studies.

Also consistent with prior studies, the researchers found that women tended to be more fearful about transplants than men, with 26 percent of women saying they feared a transplant compared to less than eight percent of the men.

Women do just as well after a transplant as men, if not better, Segev said. “That’s another area where we need to work on education and assurance,” he said.

In sum, he said, the study points to a lack of education for renal-failure patients about the benefits of kidney transplants.

“This is another set of evidence that we have a problem in how well we are educating people at the time of their kidney disease,” he said. “We really need to find a better way to educate people about transplantation.”

Jesse Schold agreed. He has done similar research at the Cleveland Clinic but was not involved with the current study.

“The preponderance of research shows that transplantation doubles life expectancy, improves quality of life and reduces healthcare costs,” he told Reuters Health.

“It’s certainly interesting and to most people would be relatively startling” to realize how many patients aren’t pursuing transplantation because they say they’re doing fine, he said.

“Given the overwhelming evidence that transplantation is a better treatment modality, it certainly suggests that more education may be appropriate.”

Schold stressed the need for patients suffering from renal failure to see nephrologists and learn about transplants soon after they are diagnosed with renal problems.

Prior research found that kidney-disease patients who are African-American or lack private health insurance are less likely to be matched with donor organs before they need dialysis.

Almost 66 percent of the current study participants were African-American. Some 24 percent of them reported feeling uncomfortable asking someone to donate a kidney, compared to 41 percent of other participants.

Americans who receive kidneys from unrelated live donors tend to be white, highly educated and live in wealthier neighborhoods, according to an earlier study.

A kidney is one of the few organs people can give away and go on to live a healthy life.

Since the 1990s, advances in immune-suppression have made it safer to receive an organ from someone who’s not a relative. Less-invasive surgical techniques also make it easier to donate.

- Reuters